Doximity's stock price has fallen from $65 to $25 in six months, a decline attributed mainly to market overreaction and short-term uncertainties rather than weakening business fundamentals. The company maintains strong financial health with 90% gross margins, about 30% net margins, and solid cash generation, supported by a dominant network of U.S. healthcare professionals. Although recent growth has slowed and there are concerns about pharmaceutical client budgets, Doximity remains asset-light with minimal downside risk and good liquidity. The stock is rated a cautious buy due to undervaluation and resilient profitability, while investors should watch developments in AI monetization and client budget trends.
Law Offices of Howard G. Smith reminds investors of upcoming deadlines to file lead plaintiff motions in securities fraud class actions involving Badger Meter, PicS N.V., Verra Mobility, and Grail, Inc. The lawsuits allege these companies made mislea...
Assembli Events & Production is creating the Big Ten Conference's first fan activation at Fanatics Fest NYC, held July 16-19, 2026. This event marks the Big Ten as the first collegiate conference to join the premier sports fan festival, showcasing tr...
State Street posted strong Q2 results with earnings per share of $3.65, beating estimates and up from $2.53 last year. Quarterly revenue reached $4.05 billion, driven by a 17.2% rise in fee revenues and 18% growth in net interest income. Assets under...
U.S. farmers face high and unstable fertilizer prices due to global shipping disruptions, with nearly 70% unable to afford needed fertilizer this season. Denali Water Solutions provides a natural, low-cost fertilizer alternative made from recycled or...
Denodo Technologies released Platform 9.5, improving its AI data layer by providing trusted, governed enterprise context for AI, analytics, and data sharing. Key features include an expanded enterprise knowledge graph, metric views for consistent bus...
